Núria Buil‐Bruna - Concepedia

Author

Núria Buil‐Bruna

AstraZeneca (United States)

Also Known As

N. Buil-Bruna, Nuria Buil-Bruna, Núria Buil-Bruna, Núria Buil‐Bruna

Publications

257

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United States)Universidad de Navarra AstraZeneca (Sweden)AstraZeneca (United Kingdom)AstraZeneca (Finland)

About

Núria Buil‐Bruna is an author at AstraZeneca (United States) specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	86
2	Public Health	1	1	15
3	Biostatistics	1	1	15
4	Health Informatics	1	1	15
5	Molecular Biology	1	1	17

Núria Buil‐Bruna

Publications

202

Citations

H-Index

Page 1

	Year	Citations
Brain exposure of the ATM inhibitor AZD1390 in humans—a positron emission tomography study Aurelija Jučaitė, Per Stenkrona, Zsolt Cselényi, Neuro-Oncology	2020	63
A Population Pharmacodynamic Model for Lactate Dehydrogenase and Neuron Specific Enolase to Predict Tumor Progression in Small Cell Lung Cancer Patients Núria Buil‐Bruna, José M. López-Picazo, Marta Moreno, The AAPS Journal Neuron Specific EnolaseMedicineLactate DehydrogenasePharmacologyPathology	2014	32
Semimechanistic Cell-Cycle Type–Based Pharmacokinetic/Pharmacodynamic Model of Chemotherapy-Induced Neutropenic Effects of Diflomotecan under Different Dosing Schedules Víctor Mangas‐Sanjuan, Núria Buil‐Bruna, Marı́a J. Garrido, Journal of Pharmacology and Experimental Therapeutics	2015	28
Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors Núria Buil‐Bruna, Marion Dehez, Amandine Manon, The AAPS Journal Progression-free SurvivalSurgical OncologyEndocrine OncologyGastrointestinal OncologyMedicine	2016	22
Abstract A094: Phase I modular study of AZD0156, a first-in-class oral selective inhibitor of ataxia telangiectasia mutated protein kinase (ATM), in combination with olaparib (AToM Study, Module 1) Wassim Abida, Yung Jue Bang, Louise Carter, Molecular Cancer Therapeutics Molecular BiologyPathologyPharmacotherapyAtom StudyMetronomic Chemotherapy	2018	17
Early Prediction of Disease Progression in Small Cell Lung Cancer: Toward Model-Based Personalized Medicine in Oncology Núria Buil‐Bruna, Tarjinder Sahota, José M. López-Picazo, Cancer Research Disease ProgressionPrognosisCt Scan DataComputational MedicineOncology	2015	15
Exposure–response analysis of acalabrutinib and its active metabolite, ACP‐5862, in patients with B‐cell malignancies Helena Edlund, Núria Buil‐Bruna, Karthick Vishwanathan, British Journal of Clinical Pharmacology	2021	15
Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP‐5862, in patients with B‐cell malignancies and in healthy subjects using a population pharmacokinetic approach Helena Edlund, Francesco Bellanti, Huan Liu, British Journal of Clinical Pharmacology	2021	10

Page 1